

Pharmacy & Therapeutics Update

From the February & May meetings of the SHC Pharmacy and Therapeutics Committee
For further information, contact Dana Radman, pharmacy manager and committee secretary:

DRadman@stanfordmed.org

Added to the formulary:

1. **Sofosbuvir (Sovaldi®)** is an oral hepatitis C virus (HCV) NS5B protease inhibitor that inhibits viral replication. It is indicated for treatment of Hepatitis C genotype 1 and 4 infection with ribavirin and peg-interferon, and genotype 2 and 3 infection with ribavirin. The most common adverse reactions are fatigue, headache, pruritus, asthenia and insomnia. Drugs that are potent P-gp inducers increase the metabolism of sofosbuvir and decrease its plasma concentration. The Committee approved the addition of sofosbuvir to the formulary with the following restrictions:
 - a. Restricted to the hepatology and infectious diseases services
2. **Simeprevir (Olysio®)** is an oral hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C infection in combination with ribavirin and peg-interferon. The most common adverse reactions were rash (including photosensitivity), pruritis, and nausea; myalgia and dyspnea were also reported. Drug interactions may occur with moderate or strong inducers or inhibitors of CYP3A, and concurrent use is not recommended. The Committee approved the addition of simeprevir to the formulary with the following restrictions:
 - a. Restricted to the hepatology and infectious diseases services
3. **Lanreotide (Somatuline Depot®)** is a once-monthly subcutaneous somatostatin analog, which works to inhibit specific endocrine, neuroendocrine, and exocrine mechanisms, and is used by the oncology service in treatment of neuroendocrine tumors. The most common adverse reactions are bradycardia, diarrhea, abdominal pain, flatulence, nausea, weight loss, anemia, cholelithiasis, and injection site reaction. The Committee approved the addition of lanreotide to the formulary.

Removed from the formulary:

None